Latest news

• GSK sells eczema and psoriasis drug to Dermavant for £250m

  In the case of psoriasis, that includes not only new therapies such as Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Johnson &Johnson’s IL-23/IL-12 inhibitor Tremfya (guselkumab), but

• UK, Germany back routine use of J&J’s Tremfya

  Further assessments of Tremfya are currently underway in a number of other countries in the EU, with decisions anticipated later in the year, according to the drugmaker. ... J&J is hoping that Tremfya will help it defend the lucrative franchise as

• Sun Pharma passes milestone with novel psoriasis drug approval

  IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

• AbbVie reports more solid data for would-be psoriasis blockbuster

  AbbVie’s drug is in hot pursuit of the only approved IL-23 inhibitor on the market - J&J’s Tremfya (guselkumab) - and some analysts including Leerink’s Geoffrey Porges have

• Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

  as well as Johnson &Johnson’s IL-23 blocker Tremfya (guselkumab) which was approved in Europe towards the end of last year.